GlaxoSmithKline (GSK) rejects the conclusions about the safety of Avandia (rosiglitazone) reported in the February 20, 2010, New York Times story.

Further information:

Article source

Related posts:

1. Will GSK Take Avandia Off the Market or Not?
2. Robotic Surgery Expert Dr. David Samadi, MD Discusses New York Times Article on the Dangers of Radiation Therapy for Prostate Cancer Treatment
3. FDA: No new conclusions on Glaxo’s Avandia yet
4. FDA reports says Avandia can hurt heart: report
5. GSK Consumer Healthcare warns consumers of potential health risks associated with long-term excessive use of zinc-containing denture adhesives